" For the first iteration of an experiment , these results are simply remarkable , " says Nasser Zolfaghari , who has also previously worked at Harvard ' s Department of Stem Cell and Regenerative Biology . " Our tests on mice have given remarkable results but it is only by testing the vaccine on human subjects that suffer from these genetic anomalies that we can eventually know for sure the vaccine ' s efficiency on humans . In America or Europe , it could take a decade of concerted effort to get this new approach from the laboratory to Phase I clinical trials in humans . But laws in Iran will facilitate and hasten the process " he admits , visibly enthusiastic .
